AR008071A1 - Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen - Google Patents
Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienenInfo
- Publication number
- AR008071A1 AR008071A1 ARP970103330A ARP970103330A AR008071A1 AR 008071 A1 AR008071 A1 AR 008071A1 AR P970103330 A ARP970103330 A AR P970103330A AR P970103330 A ARP970103330 A AR P970103330A AR 008071 A1 AR008071 A1 AR 008071A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- straight
- composition
- lower alkyl
- branched chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Abstract
Abarca los compuestos de la fórmula (I), en la cual uno de los X1, X2 y X3 es fórmula (II), y el resto de los miembros del grupo X1, X2 y X3 sonhidrógeno; y Q es nitrógeno u oxígeno; D está ausente cuando Q es oxígeno y cuando Q es nitrógeno, Des hidrógeno, alquilo inferior de cadena recta oramificada con 1 a 6 átomos de carbono, o puede estar unido con G para formar un anillo; E es O o H2; o y r son 0 o 1; G es alquilo inferior de cadenarecta o ramificada con 1 a 6 átomos de carbono, arilo, arilo sustituido con halógeno, alquilo inferior de cadena recta o ramificada con 1 a 6 átomos decarbono, heteroarilo seleccionado entre el grupo que consiste en 2-, 3- o 4- piridilo, 2-pirazilo, 2- o 3-tienilo, 2-pirazinilo, 2-, 3- o 4-quinolilo, 1-,3- o 4-isoquinolilo, 2-quinoxalilo, 3- o 4-cinolilo, heteroarilo sustituido con halógeno, hidroxi, alquilo inferior de cadena recta o ramificada con 1 a 6átomos de carbono, alcoxi inferior de cadena recta o ramificada con 1 a 6átomos de carbono; o está unido a D para formar un anillo; Ar es un grupoarilo preferentemente seleccionado entre el grupo que consiste en fenilo, 2- 3- o 4-piridilo, 2- o 3-tienilo, 2-, 4- o 5-pirimidilo, cada uno de los cualeses optativamente mono- o disustituido con halógeno, hidroxi, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; B es azufre,oxígeno, N(R5) o C(R5)(R6); n es 1, 2 o 3; m es 2, 3 o 4; A y T son iguales o diferentes y representan hidrógeno, halógeno, hidroxi, alquilo inferior decadena recta o ramificada con 1 a 6 átomos de carbono, o alcoxi inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R1 y R2 son igualeso diferentes y representan hidrógeno, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R3 y R4 son iguales o diferentes y
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2229896P | 1996-07-23 | 1996-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR008071A1 true AR008071A1 (es) | 1999-12-09 |
Family
ID=21808875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970103330A AR008071A1 (es) | 1996-07-23 | 1997-07-23 | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen |
Country Status (20)
Country | Link |
---|---|
US (2) | US6133265A (es) |
EP (1) | EP0918761B1 (es) |
JP (1) | JP2000515527A (es) |
AR (1) | AR008071A1 (es) |
AT (1) | ATE239002T1 (es) |
AU (1) | AU3671897A (es) |
CA (1) | CA2260983A1 (es) |
CO (1) | CO4890841A1 (es) |
DE (1) | DE69721541T2 (es) |
DK (1) | DK0918761T3 (es) |
ES (1) | ES2197354T3 (es) |
HR (1) | HRP970412A2 (es) |
ID (1) | ID17453A (es) |
MA (1) | MA26435A1 (es) |
PA (1) | PA8434601A1 (es) |
PE (1) | PE1999A1 (es) |
PT (1) | PT918761E (es) |
TN (1) | TNSN97127A1 (es) |
WO (1) | WO1998003494A1 (es) |
ZA (1) | ZA976470B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT918761E (pt) * | 1996-07-23 | 2003-09-30 | Neurogen Corp | Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1 |
SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
EP1299362A4 (en) * | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE |
MXPA03000174A (es) | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP1620091B1 (en) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP2007502287A (ja) | 2003-08-13 | 2007-02-08 | アムジェン インコーポレイテッド | メラニン凝集ホルモン受容体アンタゴニスト |
NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
JP4996926B2 (ja) | 2004-02-05 | 2012-08-08 | プロビオドルグ エージー | グルタミニルシクラーゼの新規の阻害剤 |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
ES2656017T3 (es) * | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
JP2009521468A (ja) * | 2005-12-24 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Abc輸送体の調節因子としてのキノリン−4−オン誘導体 |
PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
EP1834953A1 (en) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
CA2865519C (en) | 2012-02-27 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
WO2020172609A1 (en) * | 2019-02-21 | 2020-08-27 | Marquette University | Heterocyclic ligands of par1 and methods of use |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
NZ233401A (en) * | 1989-04-22 | 1991-03-26 | Wyeth John & Brother Ltd | Piperazine derivatives and pharmaceutical compositions |
US5900415A (en) * | 1994-11-07 | 1999-05-04 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
JP2000515151A (ja) * | 1996-07-23 | 2000-11-14 | ニューロジェン・コーポレーション | 特定の置換ベンジルアミン誘導体;新規クラスの神経ペプチド―y1特異的リガンド |
PT918761E (pt) * | 1996-07-23 | 2003-09-30 | Neurogen Corp | Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1 |
DK0915859T3 (da) * | 1996-07-23 | 2003-03-03 | Neurogen Corp | Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander |
-
1997
- 1997-07-18 PT PT97933564T patent/PT918761E/pt unknown
- 1997-07-18 US US08/897,046 patent/US6133265A/en not_active Expired - Fee Related
- 1997-07-18 ES ES97933564T patent/ES2197354T3/es not_active Expired - Lifetime
- 1997-07-18 CA CA002260983A patent/CA2260983A1/en not_active Abandoned
- 1997-07-18 DE DE69721541T patent/DE69721541T2/de not_active Expired - Fee Related
- 1997-07-18 AT AT97933564T patent/ATE239002T1/de not_active IP Right Cessation
- 1997-07-18 EP EP97933564A patent/EP0918761B1/en not_active Expired - Lifetime
- 1997-07-18 JP JP10507143A patent/JP2000515527A/ja not_active Ceased
- 1997-07-18 DK DK97933564T patent/DK0918761T3/da active
- 1997-07-18 AU AU36718/97A patent/AU3671897A/en not_active Abandoned
- 1997-07-18 WO PCT/US1997/012690 patent/WO1998003494A1/en active IP Right Grant
- 1997-07-21 TN TNTNSN97127A patent/TNSN97127A1/fr unknown
- 1997-07-22 PE PE1997000652A patent/PE1999A1/es not_active Application Discontinuation
- 1997-07-22 MA MA24730A patent/MA26435A1/fr unknown
- 1997-07-22 ZA ZA976470A patent/ZA976470B/xx unknown
- 1997-07-23 AR ARP970103330A patent/AR008071A1/es unknown
- 1997-07-23 CO CO97041974A patent/CO4890841A1/es unknown
- 1997-07-23 PA PA19978434601A patent/PA8434601A1/es unknown
- 1997-07-23 ID IDP972554A patent/ID17453A/id unknown
- 1997-07-23 HR HR60/022,298A patent/HRP970412A2/hr not_active Application Discontinuation
-
2000
- 2000-08-08 US US09/633,055 patent/US6316617B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE239002T1 (de) | 2003-05-15 |
TNSN97127A1 (fr) | 2005-03-15 |
PT918761E (pt) | 2003-09-30 |
HRP970412A2 (en) | 1998-10-31 |
US6316617B1 (en) | 2001-11-13 |
EP0918761A1 (en) | 1999-06-02 |
US6133265A (en) | 2000-10-17 |
DK0918761T3 (da) | 2003-08-25 |
DE69721541D1 (de) | 2003-06-05 |
ID17453A (id) | 1998-01-08 |
ZA976470B (en) | 1998-08-04 |
JP2000515527A (ja) | 2000-11-21 |
MA26435A1 (fr) | 2004-12-20 |
EP0918761B1 (en) | 2003-05-02 |
ES2197354T3 (es) | 2004-01-01 |
PA8434601A1 (es) | 2000-05-24 |
CO4890841A1 (es) | 2000-02-28 |
AU3671897A (en) | 1998-02-10 |
DE69721541T2 (de) | 2004-03-18 |
PE1999A1 (es) | 1999-02-02 |
WO1998003494A1 (en) | 1998-01-29 |
CA2260983A1 (en) | 1998-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR008071A1 (es) | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen | |
HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
DK0468470T3 (da) | Benzimidazoler, lægemidler indeholdende sådanne forbindelser og fremgangsmåde til deres fremstilling | |
HUP0301382A2 (hu) | Alfa-aril-etanol-amin-származékok és e vegyületeket tartalmazó béta-3 adrenergiás receptor agonista hatású gyógyászati készítmények | |
DE69507505T2 (de) | Anilin derivate | |
AR028531A1 (es) | Compuestos organicos | |
BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
TR200002671T2 (tr) | Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler | |
MXPA03011324A (es) | Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa. | |
HUP0203323A2 (hu) | Tirozin kináz inhibitorok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0203228A2 (hu) | Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR013184A1 (es) | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis | |
CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
MY116952A (en) | 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation | |
DE69316067T2 (de) | Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus | |
DE602004025302D1 (de) | Aryloxy- und Arylthioxyacetophenon-Verbindungen zur Behandlung von Krebs | |
RU2010150345A (ru) | Производные хиназолина | |
UY25291A1 (es) | Procedimiento para la preparacion de isoquinolinas | |
HUP9902668A2 (hu) | Piperazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
UA72919C2 (uk) | Ароматичні аміди, заміщені рибозою, спосіб їх одержання та фармацевтична композиція | |
PE20001241A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores | |
MY125037A (en) | 1,2,3,4 tetrahydroquinoline derivatives |